Analysts expect Puma Biotechnology Inc (NASDAQ:PBYI) to post sales of $19.35 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Puma Biotechnology’s earnings. The lowest sales estimate is $17.50 million and the highest is $21.55 million. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 7th.

On average, analysts expect that Puma Biotechnology will report full year sales of $19.35 million for the current year, with estimates ranging from $23.60 million to $27.65 million. For the next financial year, analysts forecast that the firm will report sales of $236.09 million per share, with estimates ranging from $202.20 million to $296.96 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Puma Biotechnology.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same period in the prior year, the firm posted ($1.11) EPS.

Several equities analysts recently weighed in on PBYI shares. Credit Suisse Group reissued an “outperform” rating and set a $136.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, September 27th. Stifel Nicolaus boosted their price objective on Puma Biotechnology from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 2nd. BidaskClub raised Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 3rd. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $131.00 price target on shares of Puma Biotechnology in a report on Wednesday, October 4th. Finally, Citigroup reaffirmed a “buy” rating and issued a $156.00 price target (up previously from $114.00) on shares of Puma Biotechnology in a report on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. Puma Biotechnology presently has an average rating of “Buy” and a consensus target price of $130.67.

In other Puma Biotechnology news, insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total value of $139,418.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 21.10% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund raised its holdings in Puma Biotechnology by 4.7% in the 2nd quarter. New York State Common Retirement Fund now owns 32,247 shares of the biopharmaceutical company’s stock valued at $2,818,000 after acquiring an additional 1,446 shares in the last quarter. Perceptive Advisors LLC grew its stake in shares of Puma Biotechnology by 26.0% in the 3rd quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock valued at $110,627,000 after purchasing an additional 190,500 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Puma Biotechnology by 9.6% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 135,167 shares of the biopharmaceutical company’s stock valued at $16,187,000 after purchasing an additional 11,787 shares during the period. BlackRock Inc. grew its stake in shares of Puma Biotechnology by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock valued at $159,973,000 after purchasing an additional 86,924 shares during the period. Finally, Prudential Financial Inc. bought a new stake in shares of Puma Biotechnology in the 2nd quarter valued at approximately $302,000. 96.00% of the stock is owned by hedge funds and other institutional investors.

Puma Biotechnology (NASDAQ PBYI) traded down $8.40 during midday trading on Tuesday, hitting $90.85. The company had a trading volume of 1,027,342 shares, compared to its average volume of 639,870. Puma Biotechnology has a fifty-two week low of $28.35 and a fifty-two week high of $136.90. The firm has a market cap of $3,410.00, a PE ratio of -11.09 and a beta of 0.72.

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/16/analysts-anticipate-puma-biotechnology-inc-pbyi-will-post-quarterly-sales-of-19-35-million.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.